share_log

Triumph Science & Technology Co.,Ltd's (SHSE:600552) Shares Lagging The Industry But So Is The Business

Simply Wall St ·  Dec 30, 2023 19:21

With a price-to-sales (or "P/S") ratio of 2.5x Triumph Science & Technology Co.,Ltd (SHSE:600552) may be sending bullish signals at the moment, given that almost half of all the Electronic companies in China have P/S ratios greater than 4.5x and even P/S higher than 9x are not unusual. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.

View our latest analysis for Triumph Science & TechnologyLtd

ps-multiple-vs-industry
SHSE:600552 Price to Sales Ratio vs Industry December 31st 2023

What Does Triumph Science & TechnologyLtd's Recent Performance Look Like?

While the industry has experienced revenue growth lately, Triumph Science & TechnologyLtd's revenue has gone into reverse gear, which is not great. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. So while you could say the stock is cheap, investors will be looking for improvement before they see it as good value.

Keen to find out how analysts think Triumph Science & TechnologyLtd's future stacks up against the industry? In that case, our free report is a great place to start.

Do Revenue Forecasts Match The Low P/S Ratio?

In order to justify its P/S ratio, Triumph Science & TechnologyLtd would need to produce sluggish growth that's trailing the industry.

Retrospectively, the last year delivered a frustrating 13% decrease to the company's top line. At least revenue has managed not to go completely backwards from three years ago in aggregate, thanks to the earlier period of growth. So it appears to us that the company has had a mixed result in terms of growing revenue over that time.

Shifting to the future, estimates from the four analysts covering the company suggest revenue should grow by 24% over the next year. With the industry predicted to deliver 61% growth, the company is positioned for a weaker revenue result.

In light of this, it's understandable that Triumph Science & TechnologyLtd's P/S sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.

The Key Takeaway

We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

As we suspected, our examination of Triumph Science & TechnologyLtd's analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.

It is also worth noting that we have found 6 warning signs for Triumph Science & TechnologyLtd (2 are potentially serious!) that you need to take into consideration.

If these risks are making you reconsider your opinion on Triumph Science & TechnologyLtd, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment